Linked Life Data

15870882

Source:http://linkedlifedata.com/resource/pubmed/id/15870882

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15870882rdf:typepubmed:Citationlld:pubmed
pubmed-article:15870882lifeskim:mentionsumls-concept:C1704807lld:lifeskim
pubmed-article:15870882lifeskim:mentionsumls-concept:C0235782lld:lifeskim
pubmed-article:15870882lifeskim:mentionsumls-concept:C1518174lld:lifeskim
pubmed-article:15870882lifeskim:mentionsumls-concept:C0002073lld:lifeskim
pubmed-article:15870882lifeskim:mentionsumls-concept:C0011155lld:lifeskim
pubmed-article:15870882lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:15870882lifeskim:mentionsumls-concept:C1334505lld:lifeskim
pubmed-article:15870882lifeskim:mentionsumls-concept:C1155873lld:lifeskim
pubmed-article:15870882lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:15870882lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:15870882lifeskim:mentionsumls-concept:C0332324lld:lifeskim
pubmed-article:15870882pubmed:issue6lld:pubmed
pubmed-article:15870882pubmed:dateCreated2005-5-4lld:pubmed
pubmed-article:15870882pubmed:abstractTextThe aim of this study was to assess whether combined evaluation of O6-methylguanine methyltransferase (MGMT) and hMLH1 status determines sensitivity to monofuntional alkylating agents such as N-methyl-N-nitrosourea (MNU) and dacarbazine (DTIC) against gallbladder carcinoma cells. The molecular mechanism behind MGMT and hMLH1 status affecting the cell cycle was also addressed. Using 5 gallbladder cancer carcinoma lines and 1 colon carcinoma cell line (SW48), MGMT and hMLH1 expression was analyzed using RT-PCR and Western blotting. MGMT and hMLH1 status in the 6 cell lines was compared with drug sensitivity to MNU. As a result, cell lines that were MGMT-/hMLH1+ had the highest sensitivity to MNU, compared with MGMT+/hMLH1+ and MGMT-/hMLH1- cells. In flow cytometric analysis, G2-M cell cycle arrest was specifically observed in GB-d1 cells with MGMT-/hMLH1+ and expression of cyclin A and Cdc2 in GB-d1 cells was significantly reduced by MNU treatment, but not observed in KMG-C cells with MGMT+/hMLH1+. Finally, we assessed the in vitro and in vivo effect of the clinically used alkylating agent DTIC in these cells. The highest sensitivity to DTIC was also observed in MGMT-/hMLH1+. In conclusion, MNU suppressed cell proliferation of MGMT-/hMLH1+ gallbladder carcinoma cells by arresting the cell cycle at the G2-M phase, accompanied by down-regulation of cyclin A and Cdc2. These results indicated that expression of MGMT and hMLH1 could be used to select candidates for alkylating agent chemotherapy against gallbladder carcinoma.lld:pubmed
pubmed-article:15870882pubmed:languageenglld:pubmed
pubmed-article:15870882pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:citationSubsetIMlld:pubmed
pubmed-article:15870882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15870882pubmed:statusMEDLINElld:pubmed
pubmed-article:15870882pubmed:monthJunlld:pubmed
pubmed-article:15870882pubmed:issn1019-6439lld:pubmed
pubmed-article:15870882pubmed:authorpubmed-author:NöllG NGNlld:pubmed
pubmed-article:15870882pubmed:authorpubmed-author:MiyazakiKohji...lld:pubmed
pubmed-article:15870882pubmed:authorpubmed-author:KohyaNaohikoNlld:pubmed
pubmed-article:15870882pubmed:authorpubmed-author:KitajimaYoshi...lld:pubmed
pubmed-article:15870882pubmed:authorpubmed-author:KogaYasuoYlld:pubmed
pubmed-article:15870882pubmed:authorpubmed-author:MiyoshiAtsush...lld:pubmed
pubmed-article:15870882pubmed:issnTypePrintlld:pubmed
pubmed-article:15870882pubmed:volume26lld:pubmed
pubmed-article:15870882pubmed:ownerNLMlld:pubmed
pubmed-article:15870882pubmed:authorsCompleteYlld:pubmed
pubmed-article:15870882pubmed:pagination1653-61lld:pubmed
pubmed-article:15870882pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:meshHeadingpubmed-meshheading:15870882...lld:pubmed
pubmed-article:15870882pubmed:year2005lld:pubmed
pubmed-article:15870882pubmed:articleTitleDeficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest.lld:pubmed
pubmed-article:15870882pubmed:affiliationDepartment of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan.lld:pubmed
pubmed-article:15870882pubmed:publicationTypeJournal Articlelld:pubmed